OBJECTIVES: HIV-infected children may be at risk for premature cardiovascular disease. We compared levels of biomarkers of vascular dysfunction in HIV-infected children (with and without hyperlipidaemia) with those in HIV-exposed, uninfected (HEU) children enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS), and determined factors associated with these biomarkers. METHODS: A prospective cohort study was carried out. Biomarkers of inflammation [C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP1)], coagulant dysfunction (fibrinogen and P-selectin), endothelial dysfunction [soluble intracellular cell adhesion molecule-1 (sICAM), soluble vascular cell adhesion molecule-1 (sVCAM) and E-selectin], and metabolic dysfunction (adiponectin) were measured in 226 HIV-infected and 140 HEU children. Anthropometry, body composition, lipids, glucose, insulin, HIV disease severity, and antiretroviral therapy were recorded. RESULTS: The median ages of the children were 12.3 years in the HIV-infected group and 10.1 years in the HEU group. Body mass index (BMI) z-scores, waist and hip circumferences, and percentage body fat were lower in the HIV-infected children. Total and non-high-density lipoprotein (HDL) cholesterol and triglycerides were higher in HIV-infected children. HIV-infected children also had higher MCP-1, fibrinogen, sICAM and sVCAM levels. In multivariable analyses in the HIV-infected children alone, BMI z-score was associated with higher CRP and fibrinogen, but lower MCP-1 and sVCAM. Unfavourable lipid profiles were positively associated with IL-6, MCP-1, fibrinogen, and P- and E-selectin, whereas increased HIV viral load was associated with markers of inflammation (MCP-1 and CRP) and endothelial dysfunction (sICAM and sVCAM). CONCLUSIONS: HIV-infected children have higher levels of biomarkers of vascular dysfunction than do HEU children. Risk factors associated with higher biomarkers include unfavourable lipid levels and active HIV replication.
OBJECTIVES:HIV-infectedchildren may be at risk for premature cardiovascular disease. We compared levels of biomarkers of vascular dysfunction in HIV-infectedchildren (with and without hyperlipidaemia) with those in HIV-exposed, uninfected (HEU) children enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS), and determined factors associated with these biomarkers. METHODS: A prospective cohort study was carried out. Biomarkers of inflammation [C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP1)], coagulant dysfunction (fibrinogen and P-selectin), endothelial dysfunction [soluble intracellular cell adhesion molecule-1 (sICAM), soluble vascular cell adhesion molecule-1 (sVCAM) and E-selectin], and metabolic dysfunction (adiponectin) were measured in 226 HIV-infected and 140 HEU children. Anthropometry, body composition, lipids, glucose, insulin, HIV disease severity, and antiretroviral therapy were recorded. RESULTS: The median ages of the children were 12.3 years in the HIV-infected group and 10.1 years in the HEU group. Body mass index (BMI) z-scores, waist and hip circumferences, and percentage body fat were lower in the HIV-infectedchildren. Total and non-high-density lipoprotein (HDL) cholesterol and triglycerides were higher in HIV-infectedchildren. HIV-infectedchildren also had higher MCP-1, fibrinogen, sICAM and sVCAM levels. In multivariable analyses in the HIV-infectedchildren alone, BMI z-score was associated with higher CRP and fibrinogen, but lower MCP-1 and sVCAM. Unfavourable lipid profiles were positively associated with IL-6, MCP-1, fibrinogen, and P- and E-selectin, whereas increased HIV viral load was associated with markers of inflammation (MCP-1 and CRP) and endothelial dysfunction (sICAM and sVCAM). CONCLUSIONS:HIV-infectedchildren have higher levels of biomarkers of vascular dysfunction than do HEU children. Risk factors associated with higher biomarkers include unfavourable lipid levels and active HIV replication.
Authors: Dian-sheng Zhong; Xiang-huai Lu; Brian S Conklin; Peter H Lin; Alan B Lumsden; Qizhi Yao; Changyi Chen Journal: Arterioscler Thromb Vasc Biol Date: 2002-10-01 Impact factor: 8.311
Authors: G W Cockerill; T Y Huehns; A Weerasinghe; C Stocker; P G Lerch; N E Miller; D O Haskard Journal: Circulation Date: 2001-01-02 Impact factor: 29.690
Authors: E Vicenzi; M Alfano; S Ghezzi; A Gatti; F Veglia; A Lazzarin; S Sozzani; A Mantovani; G Poli Journal: J Leukoc Biol Date: 2000-09 Impact factor: 4.962
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Gayatri Mirani; Paige L Williams; Miriam Chernoff; Mark J Abzug; Myron J Levin; George R Seage; James M Oleske; Murli U Purswani; Rohan Hazra; Shirley Traite; Bonnie Zimmer; Russell B Van Dyke Journal: Clin Infect Dis Date: 2015-08-12 Impact factor: 9.079
Authors: Marcia Wong; Stephanie Shiau; Michael T Yin; Renate Strehlau; Faeezah Patel; Ashraf Coovadia; Lisa K Micklesfield; Louise Kuhn; Stephen M Arpadi Journal: J Pediatr Date: 2016-02-26 Impact factor: 4.406
Authors: Meghan F Hogan; Amy W Liu; Michael J Peters; Joshua R Willard; Zaheen Rabbani; Erik C Bartholomew; Adam Ottley; Rebecca L Hull Journal: Endocrinology Date: 2017-02-01 Impact factor: 4.736
Authors: Salma S Syed; Rula S Balluz; Edmond K Kabagambe; William A Meyer; Susan Lukas; Craig M Wilson; Bill G Kapogiannis; Sharon A Nachman; John W Sleasman Journal: AIDS Res Hum Retroviruses Date: 2012-12-03 Impact factor: 2.205
Authors: Stacy D Fisher; Thomas J Starc; Vitor Guerra; Paige L Williams; James D Wilkinson; Steven E Lipshultz Journal: Am J Cardiol Date: 2016-01-14 Impact factor: 2.778